About the Company
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 14, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Second Quarter 2025 Financial and Business Results Conference ...
Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, Aug. 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: ...
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2024 Earnings Call ...
Protalix BioTherapeutics, Inc. (AMEX: PLX) Q4 2024 Earnings Call Transcript March 17, 2025 Protalix BioTherapeutics, Inc. beats earnings expectations. Reported EPS is $0.09, expectations were $0.07.
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and ...
Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 Mar. 07, 2024 6:50 AM ET Protalix BioTherapeutics, Inc. (PLX) ...
Protalix BioTherapeutics Inc. Reveals Fall In Full Year Bottom Line
(RTTNews) - Protalix BioTherapeutics Inc. (PLX) announced earnings for full year that decreased from the same period last year The company's earnings totaled $2.93 million, or $0.04 per share.
Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice ...
CARMIEL, Israel, July 21, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of ...
Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®
CARMIEL, Israel, June 30, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of ...
Is Protalix BioTherapeutics, Inc. (PLX) The Best Rated Penny Stock To ...
Protalix was founded by Yoseph Shaaltiel in 1993. Protalix BioTherapeutics, Inc. (NYSE:PLX) showcases an impressive upside potential of 1,422%, indicating a highly optimistic outlook from analysts.
Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript
On July 4, 2025, tax reform legislation was enacted in the United States through the passage of H.R.1, The One Big Beautiful Bill Act, which includes significant corporate tax changes, including a ...
Similar Companies
Loading the latest forecasts...